Gilead’s Trodelvy, with Keytruda, Cuts Breast Cancer Risk by 35% in Trial
Bandar Seri Begawan: Gilead Sciences’ Trodelvy in combination with Merck’s blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by